Cancer Biomarkers- Market Insights, Competitive Landscape, and Market Forecast - 2027

Cancer biomarkers market by type (protein, genetic, and others), by cancer type (breast, lung, colorectal, prostate, and others), by technology (omics, imaging, immunoassay, and others), by application (diagnostics, drug delivery, prognostics, and others), and by geography is expected to advance at a respectable CAGR forecast till 2027 owing to the rising prevalence of cancer worldwide, increase in the risk factors for cancer development, the increasing research & development activities leading to new product launches and approvals in the cancer biomarkers arena across the globe

The global Cancer Biomarkers Market is estimated to grow at a CAGR of 13.73% during the forecast period from 2022 to 2027. The Cancer Biomarkers market is observing an optimistic market growth owing to an increase in the prevalence of various types of cancers globally, the growing population with risk factors for cancer development such as smoking, and high-fat diet, among others, and the increasing research & development activities in the cancer biomarkers arena leading to new product launches and increasing regulatory approvals are further expected to result in appreciable revenue growth of the Cancer Biomarkers market during the forecast period (2022-2027).

Cancer Biomarkers Market Dynamics:

One of the main factors for the growth of the Cancer Biomarkers market increase in the prevalence of various types of cancers globally. As per the data cited by the World Health Organization 2022, worldwide around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020.

In addition, according to the data provided by GLOBOCAN 2021, worldwide around 19,292,789 new cancer cases were reported in 2020. As per the above-mentioned source, it has been estimated that worldwide there will be around 28,887,942 new cancer cases including 1.40 million new cases of liver, 3.63 million cases of lung, and 666 thousand new cases of kidney cancer, by 2040.

Owing to the presence of a large patient pool suffering from cancers worldwide, the diagnostic and prognostic procedures along with the research and development activities are expected to rise substantially, which would spur the market demand for cancer biomarkers during the forecast period (2022-2027).

However, certain technical issues related to sample collection and storage, high costs incurred in research and development activities, limited infrastructural facilities, and others may act as restraints for the cancer biomarkers market growth.

The Cancer Biomarkers market was negatively impacted during the COVID-19 pandemic. During the initial stage of the pandemic, the sales of all the cancer biomarker tests, diagnoses, and research activities suffered a downfall owing to the imposition of strict lockdown rules, lack of funding, and less sample collection as the majority of the healthcare facilities were involved in tackling the situation of COVID-19. Also, during the pandemic, COVID-19 patients were given more preference in terms of diagnosis and treatment, and this leads to a decreased number of diagnoses and treatments for cancer unless and until the cases involved emergencies or required immediate treatments. However, with the ease of lockdown restrictions, the upturn of resources, and supply chain, and the administration of the vaccine to the public, the demand for cancer biomarkers increased and is expected to grow during the forecast period from 2022 - 2027.

Cancer Biomarkers Market Segment Analysis:

Cancer Biomarkers market by type (protein, genetic, and others), cancer type (breast, lung, colorectal, prostate, and others), technology (Omics, imaging, immunoassay, and others), application (diagnostics, drug delivery, prognostics, and others), and geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the cancer type segment of the cancer biomarkers market, the breast cancer segment is expected to have a significant revenue share in the year 2021. This can be attributed to the growing prevalence of breast cancer around the world, the growing number of government initiatives to reinforce timely diagnosis and treatment, along with the rising research and developmental activities in the breast cancer biomarkers segment during the forecast period.

As per the World Health Organization (WHO) 2021 data, in 2020 breast cancer was diagnosed in 2.3 million women globally. Further, as per the same source by the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the last 5 years, making it the world's most prevalent cancer.

Moreover, another key factor that is responsible for the growth of the breast cancer diagnostics market is the rising number of initiatives taken by specific national governments to increase awareness about early screening and diagnosis. For instance, in March 2021, WHO launched a Global Breast Cancer Initiative (GBCI) to reduce global breast cancer mortality by 2.5% per year, which would prevent 25% of breast cancer deaths by 2030 and 40% by 2040 among women under 70 years.

In May 2019, Qiagen, announced the immediate launch of its Therascreen® PIK3CA RGQ PCR Kit (therascreen PIK3CA Kit) after it received the U.S. regulatory (FDA) approval as a companion diagnostic to aid in identifying breast cancer patients eligible for treatment with PIQRAY (alpelisib), a newly approved therapy developed and marketed by Novartis.

Therefore, owing to the aforementioned factors, it is expected that the demand for cancer biomarkers in the breast cancer segment will increase, thereby propelling the overall market for Cancer Biomarkers during the forecast period from 2022-2027.

North America is expected to dominate the overall Cancer Biomarkers Market:

Among all the regions, North America is expected to dominate the global Cancer Biomarkers market in the year 2021 and is expected to do the same during the forecast period from 2022-2027. This domination is due to the rising prevalence of various types of cancers, along with the rising product developmental activities in North America, among others.

As per the figures mentioned by the American Cancer Society 2021, it was estimated that 1.9 million new cancer cases have been diagnosed in the United States in the year 2021. Also, according to the data provided by the Centers for Disease Control and Prevention (CDC) 2021, around 1,752,735 new cases of cancer were reported in the US in 2019. These staggering numbers of cancer prevalence are further expected to bolster the demand for more cancer biomarker identification as early diagnosis is the only way to fight cancer.

In December 2021, The US Food and Drug Administration (FDA) granted premarket approval for Thermo Fisher Scientific's Oncomine Dx Target Test as a companion diagnostic (CDx) to help identify non-small cell lung cancer (NSCLC) patients whose tumors carry epidermal growth factor receptor (EGFR) Exon20-insertion mutations. Thermo Fisher's Oncomine Dx Target Test simultaneously evaluates 23 genes associated with NSCLC.

Therefore, the interplay of various factors such as the presence of a large patient population, as well as product development activities such as gaining regulatory approvals by key market players in the region is expected to boost the North America cancer biomarkers market during the forecast period. 

Cancer Biomarkers Market Key Players:

Some of the key market players operating in the Cancer Biomarkers Market include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMerieux SA, BD, Merck Millipore, Agilent Technologies, Myriad Genetics, Sysmex Corporation, Hologic, Inc., Quest Diagnostics, Centogene N.V., PerkinElmer, Inc., Siemens Healthineers, Exact Sciences, R&D Systems, Inc., BioVision, Inc., and others.

Recent Developmental Activities in the Cancer Biomarkers Market:

• In February 2022, OncoDNA, a genomic and theranostic company announced the launch of OncoDeep kit, integrating both reagents and quality control standards for the sequencing of over 600 cancer biomarkers, which provide powerful data analysis and support oncologists in the most effective and personalized treatments for cancer patients.
• In April 2021, Roche announced the launch of Elecsys Anti-p53 immunoassay for the in vitro quantitative determination of anti-p53 antibodies. This immunoassay is used to aid physicians in the diagnosis of throat cancer, bowel cancer, and breast cancer in patients, in conjunction with other diagnostic tests.
• In July 2020, Vector Laboratories launched the Glysite Scout Glycan Screening Kits enabling researchers to understand the relevance of glycomics in the collected samples for association with post-translational protein modifications and biomarkers of disease. The Vector Laboratories curated lectin selection allowed researchers to detect the presence or absence of all major surface glycan motifs in a sample, offering insight into disease progression, and determining the effectiveness of treatment or stimulus, thus allowing better characterization of cell and tissue types.

Key Takeaways from the Cancer Biomarkers Market Report Study

• Market size analysis for current Cancer Biomarkers Market size (2021), and market forecast for 5 years (2022-2027)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Cancer Biomarkers market.
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global Cancer Biomarkers market.
• Various opportunities available for the other competitor in the Cancer Biomarkers Market space.
• What are the top-performing segments in 2021? How these segments will perform in 2027.
• Which are the top-performing regions and countries in the current Cancer Biomarkers Market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Cancer Biomarkers market growth in the coming future?

Target Audience who can be benefited from this Cancer Biomarkers Market Report Study

• Cancer Biomarkers products providers
• Research and development organizations
• Cancer Biomarkers-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Cancer Biomarkers
• Various end users who want to know more about the Cancer Biomarkers market and the latest innovations in the Cancer Biomarkers market.

Frequently Asked Questions for the Cancer Biomarkers Market:

1. What are cancer biomarkers?

• Cancer biomarkers are biological molecules that help in determining the presence of cancer in a patient. They are either produced by the cancer cells or by non-cancer cells in response to cancer onset and progression. They can be identified from serum and can be used for personalized daily care in screening, diagnosis, establishing prognosis, monitoring treatment, and detecting relapse.

2. What is the global market for Cancer Biomarkers?

• The global Cancer Biomarkers Market is estimated to grow at a CAGR of 13.73% during the forecast period from 2022 to 2027.

3. What are the drivers for the global Cancer Biomarkers market?

• The Cancer Biomarkers market is witnessing positive growth due to an increase in the prevalence of various types of cancers globally, the rising population with risk factors for cancer development such as smoking, and obesity, among others, and the increasing research and development activities in the cancer biomarkers arena leading to more product launches and regulatory approvals are further expected to result in appreciable revenue growth of the Cancer Biomarkers market during the forecast period (2022-2027).

4. Who are the key players operating in the global Cancer Biomarkers market?

• Some of the key market players operating in the Cancer Biomarkers market include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMerieux SA, BD, Merck Millipore, Agilent Technologies, Myriad Genetics, Sysmex Corporation, Hologic, Inc., Quest Diagnostics, Centogene N.V., PerkinElmer, Inc., Siemens Healthineers, Exact Sciences, R&D Systems, Inc., BioVision, Inc., and others.

5. Which region has the highest share in the Cancer Biomarkers market?

• Among all the regions, North America is estimated to amass a significant revenue share in the global Cancer Biomarkers market. This domination is due to the rising prevalence of various types of cancers, the growing number of government initiatives to reinforce timely diagnosis and treatment, and the rising product developmental activities in North America, among others, during the forecast period.

Ophthalmic Drugs Market By Product Type (Prescription Drugs And Over-The-Counter Drugs), By Indication (Dry Eyes, Eye Allergy, Glaucoma, Retinal Disorders, And Others), By Drug Class (Anti-Allergic, Anti-Inflammatory, Anti-Vegf Agents, And Others), By Dosage Forms (Gels, Capsules/Tablets, Eye Drops, And Others), and by geography is expected to advance at a respectable cagr forecast till 2027 owing to the rising burden of geriatric population globally, increase in the cases of various eye disorders and problems such as cataract, glaucoma, eye allergies, infections, among others and the increasing product development activities in the ophthalmic drugs arena across the globe.

The global ophthalmic drugs market was valued at USD 35,095.30 million in 2021 and is likely to register a CAGR of 5.34% during the forecast period from 2022 to 2027 to reach USD 47,794.78 million by 2027. The Ophthalmic Drugs market is observing optimistic market growth due to an increase in the rising burden of the geriatric population globally, the growing cases of various eye disorders and problems such as cataracts, glaucoma, eye allergies, infections, among others, increasing clinical trials and product development activities in the ophthalmic drugs arena across the globe is further expected to result in appreciable revenue growth of the Ophthalmic Drugs market during the forecast period (2022-2027).

Ophthalmic Drugs Market Dynamics:

One of the main factors for the growth of the ophthalmic drugs market is the increasing geriatric population globally. According to the data provided by the WHO (2022), in 2020, about one billion people across the world were over the age of 60. The source mentioned above added by stating that by 2050, the elderly population aged 60 and above is expected to double in number representing about 2.1 billion people. Also, people in the age group of 80 and above are estimated to triple between 2020 and 2050 to reach 426 million.

In the elderly, cataracts, age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, presbyopia allergies, and infections, among others are the major causes of vision loss, and each of these conditions can be either treated or slowed using suitable ophthalmic drugs if diagnosed early.

According to the World Health Organization (2022), globally 2.2 billion people had a near or distance vision impairment in 2020 out of which in at least 1 billion cases, vision impairment could have been prevented or was yet to be addressed.

Due to such bodily changes with age, a significant increase in the old age population can be directly linked to an increase in the population suffering from various ophthalmic diseases. Therefore, the rising geriatric population requiring more medications would spur the market demand for ophthalmic drugs during the forecast period (2022-2027)

However, certain side effects associated with the use of eye drops, gels, ointments, and strict regulatory guidelines by the government cause delay in product approvals which may act as restraints for the ophthalmic drugs market growth.

The ophthalmic drugs market was moderately impacted during the COVID-19 pandemic. During the initial stage of the pandemic, the sale of ophthalmic drugs suffered a downfall owing to the imposition of strict lockdown rules, and disruption in the manufacturing, and supply of the drugs. Also, during the pandemic, COVID-19 patients were given more preference in terms of diagnosis and treatment, and this led to a decreased number of diagnoses and treatments for various ophthalmic conditions such as cataracts, dry eyes, glaucoma, macular degeneration, conjunctivitis, and others which in turn lead to the decreased demand for ophthalmic drugs, negatively impacting the growth of ophthalmic drugs market. However, with the ease of lockdown restrictions, an upturn of resources, and a supply chain, with the administration of the vaccine to the public, with the incorporation of telemedicine and e-commerce, and with the increasing number of diagnoses for ophthalmic diseases through telehealth, the demand for ophthalmic drugs is up and is expected to grow during the forecast period from 2022 - 2027.

Ophthalmic Drugs Market Segment Analysis:

Ophthalmic Drugs Market by product type (prescription drugs and over-the-counter drugs), indication (dry eyes, eye allergy, glaucoma, retinal disorders, and others), drug class (anti-allergic, anti-inflammatory, anti-VEGF agents, and others) dosage forms (gels, capsules/tablets, eye drops, and others), and geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the dosage forms segment of the ophthalmic drugs market, the eye drops segment is expected to have a significant revenue share in the year 2021. This can be attributed to their wide applicability in a variety of diseases along with the rising drug development activities such as drug launches and regulatory approvals for eye drops during the forecast period. Eye drops mainly contain a saline base which can provide moisture for the eyes and can also help to pull the redness out. They also contain medicinal ingredients in cases of eye drops recommended for vision impairments such as refractive errors and others such as glaucoma, cataract, etc. Doctors and ophthalmologists use eye drops to treat conjunctivitis, glaucoma, keratitis, and eye allergies, and also before cataract and corneal surgery.

In January 2022, Alcon, the global leader in eye care announced the European launch of the newest addition to its innovative portfolio of dry eye products - Systane®Complete Preservative-Free Lubricant Eye Drops. In a similar instance, in October 2021, Allergan, an AbbVie company, announced the U.S. Food and Drug Administration (FDA) approval of VUITY™ (pilocarpine HCl ophthalmic solution) 1.25% for the treatment of presbyopia, which is the first and only FDA-approved eye drop to treat this common and progressive eye condition.

Therefore, owing to the aforementioned factors, it is expected that the demand for eye drops will increase, thereby propelling the overall market for ophthalmic drugs during the forecast period from 2022-2027.

North America is expected to dominate the overall Ophthalmic Drugs Market:

Among all the regions, North America is expected to dominate the global Ophthalmic Drugs market in the year 2021 and is expected to do the same during the forecast period from 2022-2027. This domination is due to the rising prevalence of eye disorders such as cataracts, diabetic retinopathy, and other eye-related disorder, also the increasing geriatric population, and the rising product launches in North America region is further expected to drive the market growth during the forecast period.

According to the National Eye Institute (2020), the United States recorded 7.7 million diabetic retinopathy cases and 24 million cataract cases in 2020, and it is expected to reach 11.3 million and 38 million, respectively, by 2030. The American Association of Ophthalmology states that cataract is the major cause of visual impairment worldwide, and geriatric ophthalmic issues are emerging as prime factors in other developing countries apart from the North America region.

Along with the growing patient population associated with eye disorders, product development activities are further expected to bolster the demand for ophthalmic drugs in the upcoming years in the region.

In April 2022, Novartis' Sandoz expanded its eye drug offerings, targeting a popular ocular hypertension medication from AbbVie's Allergan. Sandoz launched the generic version of AbbVie's Combigan, a combo eye drop used for the treatment of elevated eye pressure, as the most-dispensed branded combo glaucoma medication, in the U.S.. Therefore, the interplay of various factors such as the presence of a large patient population, as well as product launches by key market players in the region is expected to boost the North American ophthalmic drugs market during the forecast period. Therefore, the interplay of the above-mentioned factors would provide a conducive growth environment for the North America Ophthalmic Drugs market during the forecast period. 

Ophthalmic Drugs Market Key Players:

Some of the key market players operating in the Ophthalmic Drugs Market include Novartis AG, Pfizer Inc., Abbvie, Inc., F. Hofmann-La Roche Ltd., Thea Pharma Inc., Bausch Health Companies Inc., Alcon, Viatris Inc., Regeneron Pharmaceuticals, Inc., Bayer AG, Santen Inc., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., Amring Pharmaceuticals Inc., Merck & Co. Inc., Coherus Biosciences, Nicox, Akorn Operating Company LLC, Senju Pharmaceutical Co., Ltd, Adenovir Pharma, and others.

Recent Developmental Activities in the Ophthalmic Drugs Market:

• In June 2022, Novartis announced the acquisition of Kedalion Therapeutics and its AcuStream™ technology, an innovative device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye.
• In April 2022, Sandoz, a Novartis division, announced the US launch of the generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5%, an AB-rated generic equivalent to AbbVie's COMBIGAN, to lower eye pressure in patients with ocular hypertension.
• In January 2020, Horizon Therapeutics' Tepezza® (teprotumumab-trbw) injection was approved by the FDA for the treatment of Thyroid Eye Disease (TED). The Tepezza injection active, a human monoclonal antibody and targeted inhibitor of a specific growth factor receptor, is the only product approved in the US to treat the rare autoimmune disorder of TED.

Key Takeaways from the Ophthalmic Drugs Market Report Study

• Market size analysis for current Ophthalmic Drugs Market size (2021), and market forecast for 5 years (2022-2027)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Ophthalmic Drugs market.
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global Ophthalmic Drugs market.
• Various opportunities are available for the other competitor in the Ophthalmic Drugs Market space.
• What are the top-performing segments in 2021? How these segments will perform in 2027.
• Which are the top-performing regions and countries in the current ophthalmic drugs Market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for ophthalmic drugs market growth in the coming future?

Target Audience who can be benefited from this Ophthalmic Drugs Market Report Study

• Ophthalmic Drugs providers
• Research and development organizations
• Ophthalmic-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Ophthalmic Drugs
• Various end users who want to know more about the ophthalmic drugs market and the latest innovations in the Ophthalmic Drugs market.

Frequently Asked Questions for Ophthalmic Drugs Market:

1. What are Ophthalmic Drugs?

• An ophthalmic drug is administered into the eye, most frequently in the form of an eye drop formulation. To treat a variety of eye diseases, topical formulations are used. These conditions might include dry eye, glaucoma, eye damage from bacteria, and bacterial infections.

2. What is the global market for Ophthalmic Drugs?

• The global ophthalmic drugs market was valued at USD 35,095.30 million in 2021 and is likely to register a CAGR of 5.34% during the forecast period from 2022 to 2027 to reach USD 47,794.78 million by 2027.

3. What are the drivers for the global Ophthalmic Drugs market?

• The Ophthalmic Drugs market is witnessing positive growth due to an increase in the rising burden of the geriatric population globally, the growing cases of various eye disorders and problems such as cataracts, glaucoma, eye allergies, infections, among others, increasing clinical trials and product development activities in the ophthalmic drugs arena across the globe is further expected to result in appreciable revenue growth of the Ophthalmic Drugs market during the forecast period (2022-2027).

4. Who are the key players operating in the global Ophthalmic Drugs market?

• Some of the key market players operating in the Ophthalmic Drugs Market are Novartis AG, Pfizer Inc., Abbvie, Inc., F. Hofmann-La Roche Ltd., Thea Pharma Inc., Bausch Health Companies Inc., Alcon, Viatris Inc., Regeneron Pharmaceuticals, Inc., Bayer AG, Santen Inc., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., Amring Pharmaceuticals Inc., Merck & Co. Inc., Coherus Biosciences, Nicox, Akorn Operating Company LLC, Senju Pharmaceutical Co., Ltd, Adenovir Pharma, and others.

5. Which region has the highest share in the Ophthalmic Drugs market?

• Among all the regions, North America is estimated to amass a significant revenue share in the global Ophthalmic Drugs market. This domination is owing to the rising prevalence of eye disorders such as cataracts, and diabetic retinopathy, the increasing geriatric population, and the rising product launch in various geographies, among others.